Narcolepsy with cataplexy (Narcolepsy Type 1) MedDRA version: 20.0 Level: PT Classification code 10028713 Term: Narcolepsy System Organ Class: 10029205 - Nervous system disorders
Conditions
Sponsors
Takeda Development Center Americas, Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The participant is aged 18 to 70 years, inclusive, at the time of signing the informed consent form (ICF). 2. The participant has body mass index (BMI) within the range 18 to 40 kilogram per square meter [kg/m^2] (inclusive). 3. The participant has an International Classification of Sleep Disorders, 3rd Edition (ICSD-3) diagnosis of narcolepsy type 1 (NT1) by polysomnography (PSG)/Multiple Sleep Latency Test (MSLT), performed within the past 10 years. 4. The participant is positive for the human leukocyte antigen (HLA) genotype HLA-DQB1*06:02 or results from cerebrospinal fluid (CSF) testing indicate the participant's CSF orexin (OX)/hypocretin-1 concentration is =65 years) yes F.1.3.1 Number of subjects for this age range 15
Exclusion criteria
Exclusion criteria: 1. The participant has a current medical disorder, other than narcolepsy with cataplexy, associated with EDS. 2. The participant has medically significant hepatic or thyroid disease. 3. The participant has a history of cancer in the past 5 years (does not apply to participants with carcinoma in situ that has been resolved without further treatment or basal cell cancer) 4. The participant has clinically significant coronary artery disease, a history of myocardial infarction, clinically significant angina, clinically significant cardiac rhythm abnormality, or heart failure. 5. The participant has a clinically significant history of head injury or head trauma. 6. The participant has history of epilepsy, seizure, or convulsion, or has a family history of inherited disorders associated with seizure (except for a single febrile seizure in childhood). 7. The participant has one or more of the following psychiatric disorders: a) Any current unstable psychiatric disorder. b) Current or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including schizoaffective disorder, major depression with psychotic features, bipolar depression with psychotic features, obsessive compulsive disorder, intellectual disability, organic mental disorders, or mental disorders due to a general medical condition as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). c) Current diagnosis or history of substance use disorder as defined in the DSM-5. d) Current active major depressive episode (MDE) or who have had an active MDE in the past 6 months. 8. The participant has a history of cerebral ischemia, transient ischemic attack (1.5 times the upper limit of normal (ULN). 12. The participant is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property, or the participant has attempted suicide within the past year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the effect of TAK-861 on excessive daytime sleepiness (EDS) as measured by sleep latency from the Maintenance of Wakefulness Test (MWT);Secondary Objective: - To assess the effect of TAK-861 on EDS as measured by the Epworth Sleepiness Scale (ESS) total score. - To assess the effect of TAK-861 on cataplexy as assessed by the weekly cataplexy rate (WCR). - To evaluate the safety and tolerability of TAK-861. ;Primary end point(s): Change from baseline to Week 8 in mean sleep latency from the MWT;Timepoint(s) of evaluation of this end point: week 8 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): - Change from baseline to Week 8 in ESS total score - WCR at week 8 - Occurrence of at least 1 treatment-emergent adverse event (TEAE);Timepoint(s) of evaluation of this end point: Week 8 | — |
Countries
Australia, Finland, France, Germany, Italy, Japan, Netherlands, Norway, Spain, Sweden, Switzerland, United States
Contacts
Public ContactStudy Registration Call Center
Takeda Development Center Americas, Inc
Outcome results
None listed